105 related articles for article (PubMed ID: 1422499)
41. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation.
Snowden JA; Kearney P; Kearney A; Cooley HM; Grigg A; Jacobs P; Bergman J; Brooks PM; Biggs JC
Arthritis Rheum; 1998 Mar; 41(3):453-9. PubMed ID: 9506573
[TBL] [Abstract][Full Text] [Related]
42. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect.
Dodi IA; Van Rhee F; Forde HC; Roura-Mir C; Jaraquemada D; Goldman JM; Madrigal JA
Cytotherapy; 2002; 4(4):353-63. PubMed ID: 12396836
[TBL] [Abstract][Full Text] [Related]
43. [Bone marrow transplantation for chronic myelogenous leukemia].
Imanari A; Shibata A
Nihon Rinsho; 1990 Sep; 48(9):2087-91. PubMed ID: 2232214
[No Abstract] [Full Text] [Related]
44. Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation.
Soiffer RJ; Alyea EP; Ritz J
J Clin Apher; 1995; 10(3):139-43. PubMed ID: 8582896
[TBL] [Abstract][Full Text] [Related]
45. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
46. Eradication of minimal residual disease during graft-versus-host reaction induced by abrupt discontinuation of immunosuppression following bone marrow transplantation in a patient with Ph1-ALL.
Kanamori H; Sasaki S; Yamazaki E; Ueda S; Hattori M; Fukawa H; Tamura T; Harano H; Matsuzaki M; Ogawa K; Mohri H; Okubo T
Transpl Int; 1997; 10(4):328-30. PubMed ID: 9249945
[TBL] [Abstract][Full Text] [Related]
47. Sudden loss of the GVL effect following use of the TNF inhibitor infliximab in a chronic myelogenous leukemia patient with chronic GVHD.
Veeraputhiran M; Mangan K
Bone Marrow Transplant; 2010 Jun; 45(6):1113-4. PubMed ID: 19820730
[No Abstract] [Full Text] [Related]
48. Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia.
Porter DL; Antin JH
Hematol Oncol Clin North Am; 1998 Feb; 12(1):123-50. PubMed ID: 9523229
[TBL] [Abstract][Full Text] [Related]
49. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect.
Higano CS; Brixey M; Bryant EM; Durnam DM; Doney K; Sullivan KM; Singer JW
Transplantation; 1990 Jul; 50(1):175-7. PubMed ID: 2368144
[No Abstract] [Full Text] [Related]
50. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
Kolb HJ; Mittermüller J; Clemm C; Holler E; Ledderose G; Brehm G; Heim M; Wilmanns W
Blood; 1990 Dec; 76(12):2462-5. PubMed ID: 2265242
[TBL] [Abstract][Full Text] [Related]
51. Homogeneous immunoglobulins following allogeneic bone marrow transplantation.
Hajdu M; Puskás E; Sipos A; Barta A; Pálóczi K; Uher F
Acta Haematol; 2003; 109(3):124-8. PubMed ID: 12714821
[TBL] [Abstract][Full Text] [Related]
52. Abrupt cessation of immunosuppression in a patient with persistent acute lymphoblastic leukaemia following allogeneic transplantation.
Rymes NL; Murray JA; Holmes JA
Clin Lab Haematol; 1996 Mar; 18(1):45-6. PubMed ID: 9118604
[TBL] [Abstract][Full Text] [Related]
53. Constrictive pericarditis and primary effusion lymphoma following allogeneic BMT for CML.
Rose H; Kulik M; Standish R; Prewett E; McLennan R; Szer J; Campbell P
Bone Marrow Transplant; 2012 Sep; 47(9):1250-1. PubMed ID: 22246087
[No Abstract] [Full Text] [Related]
54. Effects of treatment regimens on post marrow transplant relapse.
Buckner CD; Clift RA; Appelbaum FR; Storb R; Fefer A; Petersen FB; Sanders JE; Sullivan K; Thomas ED; Hansen JA
Semin Hematol; 1991 Jul; 28(3 Suppl 4):32-4. PubMed ID: 1780749
[No Abstract] [Full Text] [Related]
55. Flow cytometric analysis of lymphocyte subsets as a predictive factor for GVHD in allogeneic bone marrow transplantation.
Marin GH; Menna ME; Saba S; Klein G; Mendez MC; Bergna MI; Italiano C; Malacalza J; Perez M; Gil MA; Gardenal L; Orlando S; Mansilla E; Cánepa C; Piccinelli G
Transplant Proc; 1999 Nov; 31(7):2973-5. PubMed ID: 10578354
[No Abstract] [Full Text] [Related]
56. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient.
Elias M; Bisharat N; Goldstein LH; Raz R; Saliba W
Eur J Clin Microbiol Infect Dis; 2004 Mar; 23(3):212-4. PubMed ID: 14986163
[TBL] [Abstract][Full Text] [Related]
57. CD4+ TCR alpha beta+ T-cells developing after allogeneic bone marrow transplantation in patients with chronic myelogenous leukaemia. Dipyridamole inhibits functionally heterogeneous T-cell clones.
Bruserud O; Hamann W; Patel S; Pawelec G
Int J Immunopharmacol; 1991; 13(8):1127-35. PubMed ID: 1839991
[TBL] [Abstract][Full Text] [Related]
58. Computed tomography findings in a patient with severe graft-versus-host disease of the gut.
Tan DC; Koh LP; Tan PH
Br J Haematol; 2007 Mar; 136(6):768. PubMed ID: 17129228
[No Abstract] [Full Text] [Related]
59. Involvement of macrophages in lethal forms of graft-versus-host disease.
Facon T; Janin A; Noel MP; Jouet JP
Lancet; 1995 Feb; 345(8946):392. PubMed ID: 7845145
[No Abstract] [Full Text] [Related]
60. Graft versus leukemia in humans.
Butturini A; Gale RP
Cancer Treat Res; 1995; 76():299-314. PubMed ID: 7577341
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
